PRQR SEC Filing News — ProQR Therapeutics N.V.

PRQR insider de Boer Daniel Anton (Director, Chief Executive Officer) bought 200,000 shares (~$354.0K)

de Boer Daniel Anton, listed as Director, Chief Executive Officer at ProQR Therapeutics N.V., reported an open-market purchase of 200,000 PRQR shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

PRQR insider Filius Bart (Director) bought 150,000 shares (~$257.9K)

Filius Bart, listed as Director at ProQR Therapeutics N.V., reported an open-market purchase of 150,000 PRQR shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

PRQR insider de Boer Daniel Anton (Director, Chief Executive Officer) bought 150,000 shares (~$261.0K)

de Boer Daniel Anton, listed as Director, Chief Executive Officer at ProQR Therapeutics N.V., reported an open-market purchase of 150,000 PRQR shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

PRQR insider de Boer Daniel Anton (Director, Chief Executive Officer) bought 150,000 shares (~$238.5K)

de Boer Daniel Anton, listed as Director, Chief Executive Officer at ProQR Therapeutics N.V., reported an open-market purchase of 150,000 PRQR shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

PRQR insider Filius Bart (Director) bought 150,000 shares (~$231.0K)

Filius Bart, listed as Director at ProQR Therapeutics N.V., reported an open-market purchase of 150,000 PRQR shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

PRQR insider Form 4 filed for equity award, exercise, or tax withholding

Hinsch Gylvin Lykke (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

PRQR Form 144 filed for proposed insider sale

An insider at ProQR Therapeutics N.V. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.